secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001558370-22-016899
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Pharma Q3 net loss $22.7M; cash $222.6M; OP-1250 shows 41% tumor reduction
--------------------------------------------------------------------------------

- Net loss $22.7M in Q3 2022 vs $17.7M in Q3 2021; R&D expenses $17.6M GAAP ($14.8M non-GAAP).
- Cash, equivalents and marketable securities $222.6M at Sept 30, 2022; sufficient into H2 2024.
- OP-1250 monotherapy: 41% of heavily pre-treated patients had tumor reduction; 6 partial responses; Phase 2 fully enrolled.
- OP-1250 + palbociclib combo: dose escalation completed, Phase 2 expansion ongoing; no dose-limiting toxicities.
- Phase 3 monotherapy study planned for mid-2023; FDA Fast Track granted for ER+/HER2- metastatic breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/0001558370-22-016899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/olma-20221108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer